Replies to post #118186 on Biotech Values

[jq1234]

BIIB is an interesting story. BIIB came full circle, from merging with Idec, an oncology company, then getting out of oncology against current industry trend. Currently stock price at $80.96, approaching all time high, higher than GENZ was sold to SNY. Two Icahn engagements in recent years, two different outcomes, at least at this point. Very interesting!

[DewDiligence]

FDA approves BAX’s recombinant Factor-IX, called Rixubis:

http://finance.yahoo.com/news/fda-approves-baxter-rixubis-first-130000420.html

Rixibus competes with PFE’s Benefix; both are IV preparations, but only Rixibus is indicated for semi-weekly administration for prophylaxis.

BIIB plans to enter this market too (#msg-42643715, #msg-62038760).